In partnership with
Preoperative immunotherapy in early stage NSCLC safe and feasible
Trials with chemoimmunotherapy in metastatic TNBC show contradicting results
Is adding an immune checkpoint inhibitor to targeted therapy the right approach?
COVID-19 also affects the wellbeing of oncology professionals
Nivolumab-cabozantinib doublet is effective as first-line treatment in advanced RCC
CDK4/6 inhibitor palbociclib effective in ER+ advanced endometrial cancer
No advantage of post-operative radiotherapy in patients with stage IIIA N2 NSCLC
Dual AR/AKT blockade effective in mCRPC with PTEN loss
Adjuvant osimertinib in NSCLC reduces risk of CNS recurrence
Abemaciclib improves invasive disease-free survival in high risk early breast cancer
PD-L1 density, a new predictive biomarker in NSCLC
Bispecific antibodies targeting PD-1 and CTLA-4: new kids on the block(ade)
Nivolumab plus chemotherapy: the new standard for first-line treatment of gastric cancer?
DANUBE does not meet its primary endpoint
Lorlatinib outperforms crizotinib in ALK-positive advanced NSCLC
Top image: @ iStockPhoto: luismmolina
The content and interpretation of these conference highlights are the views and comments of the speakers/ authors.
BACK TO TOP